T. Rowe Price Associates’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $162K | Sell |
65,320
-1,501,872
| -96% | -$3.72M | ﹤0.01% | 2780 |
|
|
2025
Q1 | $3.12M | Sell |
1,567,192
-17,284
| -1% | -$34.4K | ﹤0.01% | 1409 |
|
|
2024
Q4 | $4.63M | Buy |
1,584,476
+38,515
| +2% | +$112K | ﹤0.01% | 1303 |
|
|
2024
Q3 | $5.98M | Hold |
1,545,961
| – | – | ﹤0.01% | 1243 |
|
|
2024
Q2 | $7.95M | Sell |
1,545,961
-976,629
| -39% | -$5.02M | ﹤0.01% | 1142 |
|
|
2024
Q1 | $17.7M | Buy |
2,522,590
+301,431
| +14% | +$2.11M | ﹤0.01% | 1003 |
|
|
2023
Q4 | $19.7M | Buy |
2,221,159
+47,788
| +2% | +$423K | ﹤0.01% | 959 |
|
|
2023
Q3 | $20.7M | Sell |
2,173,371
-160,460
| -7% | -$1.53M | ﹤0.01% | 910 |
|
|
2023
Q2 | $34.2M | Buy |
2,333,831
+1,430,090
| +158% | +$21M | ﹤0.01% | 811 |
|
|
2023
Q1 | $11.1M | Sell |
903,741
-1,474,841
| -62% | -$18.1M | ﹤0.01% | 1039 |
|
|
2022
Q4 | $44.2M | Buy |
+2,378,582
| New | +$44.2M | 0.01% | 696 |
|